Parma, Italy, May 26, 2021

58th ERA-EDTA Congress: Pre-Press Conference on ‘Late Breaking Clinical Abstracts’

ABSTRACT: The 58th ERA-EDTA Congress will be held on the originally scheduled dates of June 5-8, 2021, but in fully virtual form. Journalists can register and obtain full access to the virtual content. In a press briefing on June 4 at 2.00 pm CEST, experts will be informing exclusively and in advance about new data. The information given in the press briefing and the press releases are placed under embargo.

The Congress of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association) is Europe’s biggest congress on nephrology and renal replacement therapy. Top specialists in the field, not only from Europe but from all over the world, are expected and will be sharing their knowledge and discussing the latest research findings. This year, the Congress will continue as planned on the originally scheduled dates of June 5-8, 2021, but in a fully virtual form.

A day before the Congress, on June 4, at 2.00 pm CEST, we extend a cordial invitation to a ZOOM Press Conference. Various international experts will report on their studies and will discuss the latest research findings and high impact papers. The information is under embargo until the study results are presented in the ‘Late Breaking Clinical Trial” session on Sunday, June 6, 11.45-13.15.

The following speakers have been invited:
Late Breaking Clinical Trials: Embargoed until Sun, June 6, 2021, 11:45-13.15
(embargo is lifted at the beginning of each talk)

- ORALLY ADMINISTERED CSAR INHIBITOR AVACOPAN IN A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY (ACCOLADE) FOR TREATMENT OF C3 GLOMERULOPATHY
  Andrew Bomback, New York, United States of America

- INTERIM ANALYSIS OF A PHASE 2 DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF IPTACOPAN IN PRIMARY IGA NEPHROPATHY
  Jonathan Barratt, Leicester, United Kingdom

- EFFECTS OF DAPAGLIFLOZIN ON MAJOR ADVERSE KIDNEY EVENTS IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
  David Wheeler, London, United Kingdom (tbc)

- A LUNG ULTRASOUND GUIDED TREATMENT STRATEGY (LUST) IN END STAGE KIDNEY DISEASE PATIENTS AT HIGH CardioVASCULAR RISK: A RANDOMIZED MULTICENTER TRIAL
  Claudia Torino, Reggio Calabria, Italy

Late Breaking Abstracts: Embargoed until Sat, June 5, 09:30

- MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL, Christoph Wanner, Wurzburg, Germany

- DO VARIANT COVID-19 VIRUSES (SARS-COV-2) HAVE A WORSE PROGNOSIS AMONG CHRONIC HEMODIALYSIS PATIENTS? Keren Cohen Hagai, Kfar Saba, Israel (tbc)

To attend the Press Conference, please send an email with your contact details and details of the medium for which you are working to press@era-edta.org. After you have agreed not to publish any information prior to the lifting of the media embargo we will send you the link to the press conference.

ERA-EDTA Press Office
Dr. Bettina Albers
Tel. +49 3643 7764-23/mobile +49 174 2165629/email: press@era-edta.org